← Back to Screener
Oculis Holding AG Ordinary shares (OCS)
Price$27.37
Favorite Metrics
Price vs S&P 500 (26W)34.61%
Price vs S&P 500 (4W)-1.11%
Market Capitalization$2.01B
All Metrics
Book Value / Share (Quarterly)$4.27
P/TBV (Annual)4.89x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.47
Price vs S&P 500 (YTD)35.26%
EPS (TTM)$-2.45
10-Day Avg Trading Volume0.17M
EPS Excl Extra (TTM)$-2.45
EPS (Annual)$-2.42
ROI (Annual)-49.88%
Cash / Share (Quarterly)$1.77
ROA (Last FY)-41.94%
EBITD / Share (TTM)$-2.28
Cash Flow / Share (Annual)$-1.47
P/B Ratio6.28x
P/B Ratio (Quarterly)4.56x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-18.15x
ROA (TTM)-50.13%
EPS Incl Extra (Annual)$-2.42
Current Ratio (Annual)5.96x
Quick Ratio (Quarterly)5.85x
3-Month Avg Trading Volume0.27M
52-Week Price Return60.49%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.98
52-Week High$30.68
EPS Excl Extra (Annual)$-2.42
CapEx CAGR (5Y)133.49%
26-Week Price Return38.60%
Quick Ratio (Annual)5.85x
13-Week Price Return18.96%
Total Debt / Equity (Annual)0.01x
Current Ratio (Quarterly)5.96x
Enterprise Value$1,472.195
Revenue / Employee (Annual)$0
Cash / Share (Annual)$1.77
3-Month Return Std Dev41.61%
Net Income / Employee (TTM)$-2
ROE (Last FY)-50.47%
Net Interest Coverage (Annual)-9.77x
EPS Basic Excl Extra (Annual)$-2.42
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.01x
EPS Incl Extra (TTM)$-2.45
Receivables Turnover (Annual)0.00x
ROI (TTM)-61.92%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$3.98
Price vs S&P 500 (52W)30.66%
Year-to-Date Return37.91%
5-Day Price Return1.29%
EPS Normalized (Annual)$-2.42
ROA (5Y Avg)-65.45%
Month-to-Date Return3.57%
EBITD / Share (Annual)$-2.28
LT Debt / Equity (Annual)0.00x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-2.45
P/TBV (Quarterly)4.89x
P/B Ratio (Annual)4.56x
Book Value / Share (Annual)$4.27
Price vs S&P 500 (13W)18.28%
Beta0.21x
Revenue / Share (TTM)$0.00
ROE (TTM)-62.59%
52-Week Low$16.00
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.33
4.33
4.33
4.33
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
OCSOculis Holding AG Ordinary shares | — | — | — | — | $27.37 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Oculis Holding AG is a biopharmaceutical company developing topical treatments and disease-modifying therapies for ophthalmological conditions. Its pipeline includes OCS-01 for diabetic macular edema, OCS-02 for dry eye disease, and OCS-05 for acute optic neuritis and related neuro-ophthalmological disorders. The company's candidates target prevalent eye conditions including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.